Highest Incidence and Prevalence of Ulcerative Colitis Seen In Northern Europe, US, and Canada

 

Ulcerative Colitis is a chronic, inflammatory bowel disease that causes inflammation in the digestive tract. The inflammation in the digestive tract leads to ulceration of your colon and sometimes of the duodenum too. This causes blood to be present in the stools. The highest incidence and prevalence of inflammatory bowel diseases are seen in Northern Europe and the U.S. and Canada.

This inflammatory bowel disease can cause serious damage to your intestinal walls if not treated at the right time. The problem with Ulcerative Colitis is that it does not display any symptoms initially, but develops after long periods of remission when the immune system starts attacking the colon again. As a result of this continuous destruction of the innermost lining of the large intestine, there will be an overgrowth of the bacteria, Candida Albicans. This will increase the risk of colon cancer.

Symptoms of Ulcerative Colitis include excessive weight loss, abdominal pain, fever, fatigue, nausea, and cloudy or bloody diarrhea. Weight loss is due to the damage caused to the intestinal lining and subsequent diarrhea caused by the excess water and fat consumed in the daily diet. You may also suffer from abdominal bloating, constipation, and lack of appetite, due to the damage done to the intestinal lining. This causes your body to respond to the effects of an overload of bad food by providing you with excessive amounts of bad food, resulting in constant fatigue. The other symptoms of ulcerative colitis include the presence of rectal bleeding, which are due to the inflammation in the anal canal caused by the colon inflammation, and chronic fatigue.

Research has shown that genetics may play an important role in Ulcerative Colitis. If someone in your family has this disease, chances of you developing this disease are high. Other risk factors include having an unhealthy diet, poor nutritional status, and too much physical activity without enough rest. Various generics and biosimilars aid in the treatment of ulcerative colitis. In November 2020, Sandoz Canada Inc., a generics and biosimilars manufacturer and a division of the Switzerland-based multinational Novartis AG, received Health Canada authorization for Hyrimoz (adalimumab injection, reference biologic drug: Humira) for marketing in Canada. Hyrimoz, the new biosimilar, has been approved for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis.